## Gagik R Galstyan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/756704/publications.pdf

Version: 2024-02-01

687363 454955 74 939 13 30 g-index citations h-index papers 83 83 83 778 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. Diabetes Mellitus, 2022, 24, 479-486.	1.9	2
2	Actualization of the role of Vitamin B <sub>12</sub> in physiology and endocrine disorders. Klinicheskaia Meditsina, 2022, 99, 509-520.	0.1	0
3	Immunohistochemical features of the bone tissue of the lower extremities in patients with type 2 diabetes mellitus. Diabetes Mellitus, 2022, 24, 448-455.	1.9	0
4	Clinical case of long-term unrecognized primary hyperparathyroidism. Profilakticheskaya Meditsina, 2022, 25, 74.	0.6	0
5	Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation. Diabetes Mellitus, 2022, 25, 61-71.	1.9	2
6	Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes Mellitus, 2022, 25, 27-49.	1.9	13
7	Dynamics of regional mortality rates for men and women from diseases and external causes in Russia for the period 2016-2019 compared to 2020. Profilakticheskaya Meditsina, 2022, 25, 29.	0.6	2
8	ĐŸÑ€Đ,Đ¼ĐμĐ½ĐμĐ½Đ,Đμ КОВĐ~Đ"-Đ³Đ»Đ¾Đ±ÑƒĐ»Đ,Đ½Đ° Đ² Ñ,ĐμÑ€Đ°Đ;Đ,Đ, COVID-19. Eksperime	nt <b>al</b> bnaya	I Klinicheskay
9	Priority areas for the prevention of non-communicable diseases on the agenda of the 75th World Health Assembly: plans for the future. Profilakticheskaya Meditsina, 2022, 25, 7.	0.6	5
10	Clinical and demographic analysis of telemedicine $\hat{A}$ «doctor-patient $\hat{A}$ » consultations at the Endocrinology Research Centre. Problemy Endokrinologii, 2022, 68, 4-15.	0.8	2
11	Different treatment strategies in primary hyperparathyroidism during pregnancy. Endocrine, 2022, 77, 556-560.	2.3	2
12	Role of genetic factors (biology of telomeres) in cardiac rehabilitation. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3272.	1.4	0
13	«DIARISK» â€" the first national prediabetes and diabetes mellitus type 2 risk calculator. Diabetes Mellitus, 2021, 23, 404-411.	1.9	8
14	Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus. Diabetes Mellitus, 2021, 23, 532-540.	1.9	0
15	Cardiovascular mortality rate in Moscow and St. Petersburg in 2015 and 2018. Russian Journal of Cardiology, 2021, 26, 4048.	1.4	5
16	Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48â€week, multicenter, nonâ€randomized, parallelâ€group, openâ€label study. Obesity Science and Practice, 2021, 7, 368-378.	1.9	0
17	Changes in mortality rates from acute types of coronary artery disease in Russia for the period from 2015 to 2019. Russian Journal of Cardiology, 2021, 26, 4441.	1.4	4
18	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment. Diabetes Mellitus, 2021, 24, 193-197.	1.9	1

#	Article	IF	Citations
19	The Scientific Advisory board resolution: Implementation of intermittently scanned Continuous Glucose monitoring in clinical practice to improve glycemic control. Diabetes Mellitus, 2021, 24, 185-192.	1.9	3
20	Methods and problems of the nosological analysis of mortality in the period of COVID-19 pandemic. Nacional $\hat{E}^1$ noe Zdravoohranenie, 2021, 2, 51-58.	1.2	3
21	Consensus position of endocrinologists and pathologists on coding causes of death in patients with diabetes mellitus (expert opinion). Diabetes Mellitus, 2021, 24, 300-309.	1.9	2
22	Organizational aspects of vaccination against a new coronavirus infection. Nacional $\hat{E}^1$ noe Zdravoohranenie, 2021, 2, 5-11.	1.2	2
23	Oral semaglutide: the innovation in type 2 diabetes management. Diabetes Mellitus, 2021, 24, 273-281.	1.9	2
24	Leptin and leptin receptor evaluation in atherosclerotic plaques in patients with type 2 diabetes mellitus. Terapevticheskii Arkhiv, 2021, 93, 1186-1192.	0.8	0
25	Heart failure in coronary artery disease: review of medical certificates of cause of death. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3039.	1.4	1
26	Regional differences in cardiac mortality rates in Russia: the role of statistical features. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2928.	1.4	9
27	Atherosclerosis pathogenesis from the perspective of microvascular dysfunction. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3076.	1.4	2
28	Application of the method of motivational counseling in obese patients: a literature review. Profilakticheskaya Meditsina, 2021, 24, 110.	0.6	1
29	Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv, 2021, 93, 1491-1497.	0.8	6
30	Keratinocytes differentiation and wound healing in rats with streptozotocin – induced diabetes and severe hyperglycemia. Diabetes Mellitus, 2020, 23, 19-28.	1.9	2
31	Type 2 diabetes and prediabetes prevalence in patients with different risk factor combinations in the NATION study. Diabetes Mellitus, 2020, 23, 4-11.	1.9	23
32	Diabetes mellitus type 1 in adults. Diabetes Mellitus, 2020, 23, 42-114.	1.9	7
33	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	1.9	16
34	COVID-19: urgent questions for estimating morbidity, prevalence, case fatality rate and mortality rate. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2585.	1.4	20
35	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology, 2020, 25, 3919.	1.4	3
36	Indications for various options of foot deformities orthopedic correction in diabetic neuroosteoarthropathy. Diabetes Mellitus, 2020, 23, 374-385.	1.9	3

3

#	Article	IF	CITATIONS
37	A prospective randomized controlled trial of bone metabolism in patients with charcot foot. Diabetes Mellitus, 2020, 23, 12-18.	1.9	o
38	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019. Diabetes Mellitus, 2020, 23, 106-110.	1.9	0
39	Hypoglycemia and the risk of cognitive impairment and dementia in elderly and senile patients with type 2 diabetes. Diabetes Mellitus, 2020, 23, 72-87.	1.9	2
40	Multidisciplinary lifestyle management approach in patients with type 2 diabetes mellitus in real clinical practice. Results of application "Life is easy―programme in Russia. Diabetes Mellitus, 2019, 22, 115-126.	1.9	4
41	The initial level of heart rate variability determines the dynamics of the neuropathy of the autonomic nervous system and temperature sensitivity in rats with streptozotocin diabetes. Diabetes Mellitus, 2019, 22, 233-243.	1.9	3
42	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis. Diabetes Mellitus, 2019, 22, 504-514.	1.9	4
43	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	1.9	20
44	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	1.9	195
45	Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. Diabetes Mellitus, 2019, 22, 305-327.	1.9	6
46	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology, 2019, , 83-91.	1.4	12
47	Diagnostic value of ankle peak systolic velocity in diabetic patients with critical limb ischemia. Diabetes Mellitus, 2019, 22, 131-140.	1.9	O
48	Resolution on the results of the first working meeting of the scientific advisory board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy». Diabetes Mellitus, 2019, 22, 281-288.	1.9	5
49	Trends in the epidemiology of diabetic foot and lower limb amputations in Russian Federation according to the Federal Diabetes Register (2013–2016). Diabetes Mellitus, 2018, 21, 170-177.	1.9	22
50	The psychological component of comprehensive lifestyle modification program in overweight (obese) patients with type 2 diabetes mellitus. Problemy Endokrinologii, 2018, 64, 93-104.	0.8	0
51	Phenotyping animal models of diabetic peripheral neuropathy in rats: advantages and limitations. Problemy Endokrinologii, 2018, 64, 188-193.	0.8	0
52	Near-infrared fluorescence imaging with indocyanine green in diabetic patient with critical limb ischemia: a case report. Diabetes Mellitus, 2018, 21, 319-324.	1.9	2
53	Wound healing mechanisms in rats with streptozotocin-induced diabetes mellitus. Problemy Endokrinologii, 2018, 64, 292-298.	0.8	1
54	Electrical activity in rat retina in a streptozotocin-induced diabetes model. Diabetes Mellitus, 2018, 21, 356-363.	1.9	0

#	Article	IF	CITATIONS
55	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus, 2017, 20, 1-121.	1.9	142
56	Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation. Diabetes Mellitus, 2017, 20, 233-237.	1.9	2
57	Insulin glargine 300 U/ml in type 2 diabetes mellitus patients: results of the EDITION program (review). Problemy Endokrinologii, 2017, 63, 257-268.	0.8	1
58	Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy. Problemy Endokrinologii, 2017, 63, 307-319.	0.8	1
59	Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes Mellitus, 2017, 20, 286-298.	1.9	4
60	Obesity and type 2 diabetes: can we find a compromised treatment solution?. Diabetes Mellitus, 2017, 20, 270-278.	1.9	12
61	Self-Treated Hypoglycemia in Type 2 Diabetes Mellitus: Results from the Second Wave of an International Cross-Sectional Survey. Diabetes Therapy, 2016, 7, 279-293.	2.5	6
62	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Therapy, 2016, 7, 583-590.	2.5	5
63	The blood perfusion and NADH/FAD content combined analysis in patients with diabetes foot. Proceedings of SPIE, 2016, , .	0.8	6
64	Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice, 2016, 115, 90-95.	2.8	67
65	The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus, 2016, 19, 104-112.	1.9	155
66	Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. Diabetes Mellitus, 2016, 19, 229-236.	1.9	1
67	Long-term prognosis of diabetic patients with critical limb ischemia after endovascular therapy. Problemy Endokrinologii, 2016, 62, 28-29.	0.8	0
68	Neurohumoral mechanisms of keratinocytes regulation in diabetes mellitus. Diabetes Mellitus, 2016, 19, 366-374.	1.9	0
69	Costs of Hospital Stay in Specialized Diabetic Foot Department in Russia. Value in Health Regional Issues, 2015, 7, 80-86.	1.2	10
70	Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: A narrative review (预æ·èf°å²›ç´ç±»ä¼¼ç‰©åœ¨2型糖尿病治痗ä¸çš"作用:åÆè¿°æ€§ç»¼è¿°	). Journal c	of Diabetes, 20
71	Reductions in Post-Prandial Glucagon by the GLP-1 Receptor Agonist Lixisenatide Correlate to Reductions in PPG and A1C in Patients with Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2014, 38, S11-S12.	0.8	0
72	Diabetic osteoarthropathy: modern methods of therapy. Diabetes Mellitus, 2010, 13, 70-73.	1.9	3

#	Article	IF	CITATIONS
73	Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. Journal of Diabetes and Its Complications, 1994, 8, 45-50.	2.3	34
74	Multiple endocrine disorders in Werner syndrome. Endocrine Abstracts, 0, , .	0.0	0